Obesity Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration and Developments

The obesity pipeline includes more than 120 key companies continuously working to develop more than 120 obesity treatment therapies, analysis of clinical trials, therapies, mechanism of action, pathway of administration and development analytics DelveInsight.

Overview of Obesity

Obesity is a multifactorial disorder, which is often associated with many other important diseases such as diabetes, hypertension and other cardiovascular diseases, osteoarthritis and certain cancers. Managing obesity will therefore require a full range of strategies that focus on people with existing weight problems and also those at high risk of developing obesity. Therefore, prevention of childhood obesity should be considered a priority, as there is a risk of persistence into adulthood. Obesity can be described as the “new world syndrome”. Its prevalence is continuously increasing in all age groups in many developed countries of the world.

“Obesity Pipeline Insight, 2022” The DelveInsight report presents comprehensive information regarding the current clinical development scenario and growth prospects in the obesity market.

The Obesity Pipeline report includes an in-depth commercial and clinical assessment of the products in the pipeline from the preclinical development phase to the commercialization phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any) and product development activities including technology, collaborations, mergers acquisition, funding, designations and other products. – related details.

Some of the key takeaways from the Obesity Pipeline report:

  • Companies around the world are working diligently to develop new obesity treatment therapies with considerable success over the years. Obesity Key Players like – Sciwind Biosciences, BioRestorative Therapies, Takeda, Daewoong Pharmaceutical, ERX Pharmaceuticals, Aardvark Therapeutics, Eli Lily & Company, Novo Nordisk, and others are developing therapies for the treatment of obesity
  • Obesity Emerging therapies such as – XW017, Thermostem, SCO094, DWP 306001, ERX1000, ARD101, LY3502970, XW003, Tirzepatide, Semaglutide Oral, and others are expected to have a significant impact on the obesity market in the coming years.
  • In April 2021, Eli Lily & Company initiated a randomized, double-blind, placebo-controlled, Phase 3 study comparing the efficacy and safety of tirzepatide versus placebo in patients with heart failure with preserved ejection fraction and obesity . The study will continue until approximately 52 weeks after the last participant is randomized.

Therapeutic Assessment of the Obesity Pipeline

  • Obesity rating by product type
  • Obesity by stage and type of product
  • Assessment of obesity by route of administration
  • Obesity by stage and route of administration
  • Evaluation of obesity by type of molecule
  • Obesity by stage and type of molecule

DelveInsight’s Obesity Report covers more than 120 products in various stages of clinical development, such as

  • Late-stage products (Phase III)
  • Intermediate products (Phase II)
  • Product at an early stage (Phase I)
  • Candidates in the preclinical and discovery phase
  • Abandoned and Inactive Candidates
  • Route of administration

Emerging obesity drugs in various stages of clinical development include:

  • XW017: Sciwind Biosciences
  • Thermos: Biorestorative therapies
  • SCO094: Takeda
  • DWP 306001: Pharmaceutical Daewoong
  • ERX1000: Pharmaceutical ERX
  • ARD101: Aardvark Therapeutic
  • LY3502970: Eli Lily & Company
  • XW003: Sciwind Biosciences
  • Tirzepatid: Eli Lily & Company
  • Oral semaglutide: Novo Nordisk

Get a Free Sample PDF Report to Learn About Obesity Pipeline Assessment

Obesity Pipeline Analysis:

The Obesity Pipeline Report provides insights into

  • The report provides detailed information about the companies which are developing therapies for the treatment of obesity with overall therapies developed by each company for the same.
  • It accesses the various therapeutic candidates segmented into early, intermediate and advanced stages of development for the treatment of obesity.
  • Key obesity companies are involved in the development of targeted therapies with respective active and inactive (dormant or discontinued) projects.
  • Obesity Drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action and molecular type.
  • Detailed analysis of collaborations (business-to-business collaborations and business-to-university collaborations), license agreement, and funding details for future advancement of the Obesity Market.

The report is constructed using data and information from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, featured investor presentations and press releases from company/academic websites and industry-specific third-party sources. etc

Further details on obesity products are provided in the report. Download the Obesity Pipeline Report to learn more about emerging obesity therapies

Obesity Pipeline Market Drivers

  • Increase in the incidence of obesity
  • Awareness of the problem related to obesity
  • Demand for new and effective drugs

Obesity Pipeline Market Barriers

  • High cost associated with the treatment of obesity

Scope of the Obesity Pipeline Drug Insight

  • Coverage: Worldwide
  • Key Obesity Companies: Sciwind Biosciences, Biorestorative Therapies, Takeda, Daewoong Pharmaceutical, ERX Pharmaceuticals, Aardvark Therapeutics, Eli Lily & Company, Novo Nordisk and others
  • Key obesity therapies: XW017, Thermostem, SCO094, DWP 306001, ERX1000, ARD101, LY3502970, XW003, Tirzepatide, Semaglutide Oral and others
  • Therapeutic evaluation of obesity: Currently Marketed Therapies for Obesity and Emerging Therapies for Obesity
  • Obesity Market Dynamics: Obesity Market Drivers and Obesity Market Barriers

Request Sample PDF Report for Obesity Pipeline Assessment and Clinical Trials

Contents

1

Introduction to the Obesity Report

2

Executive Summary on Obesity

3

Overview of Obesity

4

Obesity – Analytical Perspective In-Depth Business Assessment

5

Obesity Pipeline Therapeutics

6

Late-stage obesity products (Phase II/III)

seven

Mid-stage Obesity Products (Phase II)

8

Early-Stage Obesity Products (Phase I)

9

Obesity Preclinical Stage Products

ten

Therapeutic evaluation of obesity

11

Inactive products against obesity

12

Analysis of company-university collaborations (license/partnership)

13

Key Obesity Companies

14

Key Obesity Products

15

Unmet Obesity Needs

16

Obesity Market Drivers and Barriers

17

Obesity future outlook and conclusion

18

Opinions of analysts on obesity

19

Annex

20

About DelveInsight

Download a sample PDF report to learn more about obesity medications and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Gaurav Bora
E-mail: Send an email
Call: +91 9568243403
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

Comments are closed.